Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Clene (CLNN) has entered into an agreement with German-based APST Research to utilize its extensive NfL database to support ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including ...

Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) da ...

The first-ever platform trial for ALS tested four drugs simultaneously, creating a faster path to finding treatments for a ...

Phosphorylated tau 217 better detected Alzheimer’s disease pathology across a range of neurodegenerative syndromes compared ...

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

The company will discontinue development of its original ALS gene therapy candidate VY9323 amid toxic effects in nonhuman ...

Discontinuation of first-line DMTs among patients with stable MS for at least 5 years may lead to an increased risk for recurrence.

A new service aimed at supporting older people who are starting to become frail, could reduce emergency hospital admissions by more than a third and save the NHS money, finds a new study led by ...